146 related articles for article (PubMed ID: 8532737)
1. A decision tree approach for carcinogen risk assessment.
Butterworth BE; Eldridge SR
Prog Clin Biol Res; 1995; 391():49-70. PubMed ID: 8532737
[TBL] [Abstract][Full Text] [Related]
2. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
Butterworth BE; Conolly RB; Morgan KT
Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive approach for integration of toxicity and cancer risk assessments.
Butterworth BE; Bogdanffy MS
Regul Toxicol Pharmacol; 1999 Feb; 29(1):23-36. PubMed ID: 10051416
[TBL] [Abstract][Full Text] [Related]
4. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
5. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
[TBL] [Abstract][Full Text] [Related]
7. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
8. Understanding population and individual risk assessment: the case of polychlorinated biphenyls.
Shields PG
Cancer Epidemiol Biomarkers Prev; 2006 May; 15(5):830-9. PubMed ID: 16702358
[TBL] [Abstract][Full Text] [Related]
9. [International-cooperative studies on carcinogenicity evaluation of environmental chemicals].
Hayashi Y
Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 2):579-84. PubMed ID: 3985632
[TBL] [Abstract][Full Text] [Related]
10. A classification framework and practical guidance for establishing a mode of action for chemical carcinogens.
Butterworth BE
Regul Toxicol Pharmacol; 2006 Jun; 45(1):9-23. PubMed ID: 16530901
[TBL] [Abstract][Full Text] [Related]
11. An adjustment factor for mode-of-action uncertainty with dual-mode carcinogens: the case of naphthalene-induced nasal tumors in rats.
Bogen KT
Risk Anal; 2008 Aug; 28(4):1033-51. PubMed ID: 18564993
[TBL] [Abstract][Full Text] [Related]
12. Cancer risk assessment at the crossroads: the need to turn to a biological approach.
Clayson DB; Iverson F
Regul Toxicol Pharmacol; 1996 Aug; 24(1 Pt 1):45-59. PubMed ID: 8921545
[TBL] [Abstract][Full Text] [Related]
13. Environmental and chemical carcinogenesis.
Wogan GN; Hecht SS; Felton JS; Conney AH; Loeb LA
Semin Cancer Biol; 2004 Dec; 14(6):473-86. PubMed ID: 15489140
[TBL] [Abstract][Full Text] [Related]
14. Overview of genotoxic carcinogens and non-genotoxic carcinogens.
Hayashi Y
Exp Toxicol Pathol; 1992 Dec; 44(8):465-71. PubMed ID: 1493365
[TBL] [Abstract][Full Text] [Related]
15. Cancer risk assessment of direct acting carcinogens.
Zito R
J Exp Clin Cancer Res; 1999 Sep; 18(3):273-8. PubMed ID: 10606168
[No Abstract] [Full Text] [Related]
16. Comparison of cancer slope factors using different statistical approaches.
Subramaniam RP; White P; Cogliano VJ
Risk Anal; 2006 Jun; 26(3):825-30. PubMed ID: 16834636
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the human relevance of chemically induced animal tumors.
Cohen SM; Klaunig J; Meek ME; Hill RN; Pastoor T; Lehman-McKeeman L; Bucher J; Longfellow DG; Seed J; Dellarco V; Fenner-Crisp P; Patton D
Toxicol Sci; 2004 Apr; 78(2):181-6. PubMed ID: 14737005
[TBL] [Abstract][Full Text] [Related]
18. Addressing nonlinearity in the exposure-response relationship for a genotoxic carcinogen: cancer potency estimates for ethylene oxide.
Kirman CR; Sweeney LM; Teta MJ; Sielken RL; Valdez-Flores C; Albertini RJ; Gargas ML
Risk Anal; 2004 Oct; 24(5):1165-83. PubMed ID: 15563286
[TBL] [Abstract][Full Text] [Related]
19. Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose.
Gaylor DW; Swirsky Gold L
Regul Toxicol Pharmacol; 1998 Dec; 28(3):222-5. PubMed ID: 10049793
[TBL] [Abstract][Full Text] [Related]
20. Analysis of in vivo mutation data can inform cancer risk assessment.
Moore MM; Heflich RH; Haber LT; Allen BC; Shipp AM; Kodell RL
Regul Toxicol Pharmacol; 2008 Jul; 51(2):151-61. PubMed ID: 18321622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
